GlassScriptPhysician profile
Kevin Schendel
NPI 1992741789
$35,227.98
in general payments reported to CMS, 2019-2025
42 companies · $1,936 in 2025
The $1,936 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,103 · 2021: $2,457 · 2022: $3,862 · 2023: $2,222 · 2024: $3,519 · 2025: $1,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,879 · Consulting Fee: $1,740 · Education: $58.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,878.69 |
| Consulting Fee | $1,740.00 |
| Education | $58.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $12,465.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $8,981.58 | 2019-2022 | |
| Abbvie INC. | $1,823.00 | 2019-2025 | Ubrelvy, Synthroid, Vraylar |
| Lilly USA, LLC | $1,757.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,530.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,022.76 | 2019-2025 | Evenity, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $769.39 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.29 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $645.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $520.42 | 2019-2025 | Belsomra, Gardasil 9, Verquvo |
| Allergan, INC. | $501.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $457.16 | 2022-2025 | |
| Amarin Pharma, INC. | $399.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $394.79 | 2019-2024 | Trelegy Ellipta |
| Abbott Laboratories | $384.79 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schendel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.